Amanta Healthcar Stock Price Today (NSE: AMANTA)

Amanta Healthcar

115.325.89 (4.86%)
Market Closed

Fundamental Score

...

Amanta Healthcar Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Amanta Healthcar share price today is 115.32, down 4.86% on NSE/BSE as of 19 June 2026. Amanta Healthcar (AMANTA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 408.81 (Cr). The 52-week high for AMANTA share price is 154.40 and the 52-week low is 92.00. At a P/E ratio of 40.16x, AMANTA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.99% and a debt-to-equity ratio of 0.88.

Amanta Healthcar Share Price Chart — NSE/BSE Historical Performance

No data
High
146.78
Low
115.32
Volume
92.8K
Change
-1.88%

Amanta Healthcar share price chart: -1.88% return over the past month. 52-week high ₹154.40, 52-week low ₹92.00.

Amanta Healthcar — Last 10 Trading Days

DateOpenHighLowCloseVolume
120.90122.30114.05115.323.56L (Cr)
125.52129.00119.70121.211.32L (Cr)
131.30134.00122.93125.512.23L (Cr)
134.78134.78131.20131.8060.66K (Cr)
129.15134.41129.15133.251.34L (Cr)
130.09135.00129.32132.271.25L (Cr)
126.61131.99125.12130.0947.65K (Cr)
127.62129.10125.41126.2446.51K (Cr)
131.00131.00125.50126.3588.97K (Cr)
126.00135.00126.00132.361.01L (Cr)

Amanta Healthcar — Last 12 Months Price History

MonthOpenHighLowCloseChange
125.52129.00114.05115.32-8.13%
131.13146.78122.00125.51-4.29%
101.92140.2599.87131.13+28.66%
99.71102.5092.0099.81+0.10%
103.80110.65100.00102.95-0.82%
109.00115.0098.25103.33-5.20%
104.50117.1297.75109.06+4.36%
121.99124.8999.99106.24-12.91%
132.60140.00119.50121.99-8.00%
145.98154.40133.71136.36-6.59%

AI Research Briefing

Powered by Gemini · 2026-04-17

Micro-cap pharma with stretched valuation and weak long-term sales growth; avoid until fundamentals improve.

Research Confidence
6.0/10Moderate
MICRO-CAP DARK HORSEBreakdown - 1M: -13.2%Expensive - P/E 40.16x vs Industry P/E 31.77x

WHAT'S HAPPENING NOW (last 2-4 weeks)

Amanta Healthcare saw mixed activity. A promoter increased their stake with open market purchases worth in late March. Bandhan Mutual Fund increased its stake above 5%. However, the stock was downgraded to 'Sell' by MarketsMOJO on April 7, 2026, citing weak long-term fundamentals despite recent quarterly improvements.

CORE STORY (THE REAL GAME)

Amanta is being priced as a high-growth, margin-expanding pharma player, leveraging its SteriPort technology in the IV fluids market. The real game is whether they can sustain this growth and margin profile in a competitive landscape.

Why Now
  • Promoter buying provides short-term support
  • Q3 FY26 showed improved profitability
  • SteriPort capacity expansion is expected to drive growth
Potential Catalysts
  • Significant order wins in export markets
  • Faster-than-expected SteriPort adoption
  • Debt reduction
Key Risks
  • Micro/SME cap: liquidity risk
  • High P/E ratio relative to industry
  • Negative 5-year sales CAGR
Institutional Activity

Promoter increased stake, but FII/DII holdings are stable.

Macro Context

Indian pharma sector is seeing increased investment, but competition is intense.

Order Book / Expansion

No major news found after live search.

Cash Flow Quality

Yes - Free Cash Flow 5Y: ₹178.99 Cr

3–6 Month Outlook

Next 3-6 months hinge on SteriPort adoption and export performance. Watch for Q4 results and any guidance on future growth.

Primary Thesis Risk

Failure to achieve sustained sales growth and margin expansion will lead to a significant correction.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

12.99%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

14.80%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

21.51%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Amanta Healthcar Valuation Check

Poor

Price to Earnings (P/E)

40.16x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

63.56%

% shares held by company founders/management

Poor

FII Holding

1.00%

% shares held by foreign institutional investors

Good

DII Holding

11.34%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-17.26%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

6.23%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

8.30%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

20.32%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

20.68%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.88x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

1.53x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

178.99 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Amanta Healthcar Fundamental Analysis & Valuation Benchmarking

Educational evaluation of AMANTA across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Strong Operating Margins (21.51%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Excellent EPS Growth (20.32% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (20.68% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Cash Generation (₹178.99 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (63.56%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

4 factors identified

Premium Valuation Risk (P/E: 40.16x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-17.26%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Weak Interest Coverage (1.53x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Amanta Healthcar vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Amanta Healthcar with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
44.5/100
115
₹408.81
40.2
Average
12.99%
Average
14.80%
Average
0.9
Good
20.68%
Excellent
8.30%
Good
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Amanta Healthcar Quarterly Performance

Latest quarterly metrics for AMANTA — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

6.23%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-17.26%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

8.30%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

20.68%

Compounded annual net profit growth over 5 years

Amanta Healthcar Technical Indicators

SMA 50, SMA 200, RSI and volume signals for AMANTA — calculated from daily price history

45RSI 14
Neutral — RSI 45

Momentum is balanced — neither overbought nor oversold.

SMA 50
121
▼ Price below SMA 50 — Short-term bearish
30-Day Avg Volume
166K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Amanta Healthcar Financial Statements

Annual income statement, balance sheet and cash flow for Amanta Healthcar (AMANTA) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Amanta Healthcar

About AMANTA (Amanta Healthcar)

Amanta Healthcar is a global pharmaceutical enterprise committed to advancing health and wellness through the development, production, and distribution of high-quality sterile liqu...id products. They are dedicated to crafting a portfolio of essential pharmaceuticals designed to meet the evolving needs of patients across diverse geographical regions. Amanta's operations are underpinned by a strong commitment to research and development, focusing on innovative formulations and delivery systems to improve therapeutic outcomes. Their core values revolve around safety, efficacy, and accessibility, ensuring that their products reach those who need them most, regardless of their location. Through unwavering dedication to quality and patient-centricity, Amanta strives to be a trusted partner in global healthcare, making a tangible difference in the lives of individuals and communities worldwide. Amanta Healthcar specializes in the manufacture of a comprehensive range of parenteral solutions, meticulously produced under stringent quality control standards. Their state-of-the-art manufacturing facilities are equipped to handle various product formats, catering to the specific requirements of healthcare providers and patients. The company's dedication to sterile manufacturing techniques ensures the safety and integrity of its products, meeting and exceeding international regulatory requirements. Amanta's portfolio includes a diverse array of large-volume parenterals, small-volume parenterals, and specialized delivery systems, such as nipple-head and steriport configurations. This broad product offering positions them as a versatile supplier of essential medications for hospitals, clinics, and other healthcare institutions globally. Amanta Healthcar's commitment extends beyond pharmaceutical manufacturing, encompassing the development and production of critical medical devices and fluid therapies. This expanded focus reflects their understanding of the holistic needs of healthcare providers and their dedication to providing comprehensive solutions. Their fluid therapy segment focuses on intravenous fluids, essential for hydration, electrolyte balance, and medication delivery. By integrating medical devices and fluid therapies into their portfolio, Amanta Healthcar demonstrates a dedication to innovation and comprehensive healthcare solutions. This strategic approach allows them to offer a more integrated and streamlined approach to patient care, further solidifying their position as a valuable partner in the global healthcare landscape.

Company Details

Symbol:AMANTA
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Bhavesh Girishbhai Patel
MD & Chairman
Ms. Nikhita Dinodia
Company Secretary & Compliance Officer
Mr. Shailesh M. Shah
President of Finance

AMANTA Share Price: Frequently Asked Questions

What is the current share price of Amanta Healthcar?

Amanta Healthcar (AMANTA) trades at ₹115.32 on NSE and BSE. Market cap ₹408.81 (Cr). Educational data only.

What is the P/E ratio of Amanta Healthcar?

Amanta Healthcar has a P/E of 40.16x vs industry average 31.77x.

What is the Bull Run score for Amanta Healthcar?

Amanta Healthcar has a Bull Run score of 44.5/100 based on 25+ financial parameters.

Does Amanta Healthcar pay dividends?

Amanta Healthcar has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Amanta Healthcar?

Amanta Healthcar has ROE of 12.99%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Amanta Healthcar?

Amanta Healthcar has debt-to-equity of 0.88.

Is Amanta Healthcar a good investment?

Bull Run gives Amanta Healthcar a score of 44.5/100. This is not investment advice — consult a SEBI-registered advisor.